What is GLUE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.88B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for GLUE?

P/E (TTM) is n/a and 52-week range is $7.64 to $25.77 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s GLUE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for GLUE?

The company profile lists revenue (TTM) near $24M, net income (TTM) near $-13.41B, EPS (TTM) near $-1.74 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Monte Rosa Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 84.5M shares outstanding, ISIN US61225M1027 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Monte Rosa Therapeutics Inc

$GLUE

Health Care · Biotechnology

IR Run Scenarios

$10.30

-0.19%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 150 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Employees

150

Website

www.monterosatx.com/

IPO

2021-06-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)